Acer held its 2025 Annual General Meeting on the 29th, approving a cash dividend of NT$1.7 per share and the amendment of its Articles of Incorporation.
The company has achieved year-on-year revenue growth for six consecutive quarters. In 2024, consolidated revenue reached NT$264.682 billion, with operating profit at NT$4.876 billion and net income after tax at NT$5.539 billion. Earnings per share stood at NT$1.84.
Acer maintains an optimistic outlook on the transformative potential of AI, actively expanding its AI-centric product portfolio across both computing and application domains. In the computing segment, Acer is integrating AI into PCs, workstations, and servers, while offering tools for learning and analysis. On the application front, the company is enhancing AI-driven solutions in areas ranging from business optimization to smart cities and smart healthcare.
In 2024, Acer introduced several Copilot+ PCs, setting a new benchmark for computing power and productivity. With technological maturity accelerating, Acer anticipates that AI PCs will account for 40% of its total PC shipments by 2025.
To address challenges such as tariffs and currency fluctuations, Acer is reinforcing both its core operations and diversified business strategy.
Chairman and CEO Jason Chen emphasized that Acer is aiming to maximize product completeness in its core PC business. This was evident at COMPUTEX 2025, where a wide array of new products—including AI PCs, gaming PCs, Chromebooks, graphics cards, and monitors—were showcased. The company is also branching into innovative devices like smart rings and AI-powered translation earbuds to stimulate new demand.
Under its multi-engine growth strategy, Acer’s new businesses now account for approximately 28.3% of total group revenue, nearly NT$100 billion, and contribute around half of the group’s profit—injecting strong momentum into the company’s overall growth. Acer currently has 13 publicly listed subsidiaries, and Jason Chen revealed that some will seek public offerings and join the so-called “Tiger Team” in the second half of 2025. Subsidiaries currently listed on the Emerging Stock Board are also planning to transition to the main board.
Acer’s Value Lab biomedical team is focused on developing personalized cancer vaccines and has built an AI-based antigen prediction platform to support this initiative. By integrating proprietary Acer technologies, the team is pushing the frontiers of AI applications in personalized cancer immunotherapy and will soon enter the experimental phase. In line with pharmaceutical regulations, Acer has updated its Articles of Incorporation to include relevant business scopes, a change that was approved at the shareholders’ meeting. With continued progress, the team is expected to become a future member of the “Tiger Team.”
Despite macroeconomic headwinds such as Trump-era tariff policies, supply chain shifts, and currency volatility, Acer remains steadfast in its commitment to growth and innovation.
Resource: 核心事業與醫療新事業發力，宏碁關注關稅、匯率挑戰
